Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 78

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 78
---
 the same terms as the August 2024 Investor Warrants, including that they have an exercise price equal to $1.50 per share, except that they were immediately exercisable upon issuance and expire on the five-year anniversary of the date of issuance.

Support Agreements

Certain of our stockholders holding in excess of 16% of our outstanding shares of Common Stock have entered into a Support Agreement, pursuant to which such stockholders have agreed, at every meeting of the holders of our Common Stock that our stockholders are requested to vote upon a proposal to approve the exercise in full of the August 2024 Common Warrants and the issuance of the August 2024 Common Warrant Shares upon exercise of the August 2024 Common Warrants, to vote all of the shares of Common Stock that they own in favor the warrant exercise proposal as well as any proposal to approve an adjournment of any such meeting of our stockholders for purposes of obtaining further votes in favor of the warrant exercise proposal that are at any time or from time-to-time presented for consideration to our stockholders.

| 41 |

<div align='center'>THE OCTOBER 2024 OFFERINGS</div>

Registered Direct Offering and Concurrent Private Placement

On October 18, 2024, we entered into the October 2024 Purchase Agreement with the certain institutional investors (the “October 2024 Investors”), pursuant to which we issued to the October 2024 Investors, (i) in a registered direct offering (the “October 2024 RD”), 2,048,294 shares (the “ October 2024 Shares”) of Common Stock, and (ii) in the concurrent October 2024 Private Placement, the October 2024 Common Warrants to purchase an aggregate of 2,662,782 shares of Common Stock (the “October 2024 Common Warrant Shares”), with an exercise price of $1.50. The October 2024 RD and October 2024 Private Placement are collectively referred to as the “October 2024 Offerings.”

The October 2024 Offerings closed on October 21, 2024 and we received aggregate gross proceeds from the October 2024 Offerings of approximately $2.7 million, excluding any proceeds that may be received upon the exercise of the October 2024 Common Warrants and before deducting placement agent fees and other offering expenses payable by us. The October 2024 Shares were offered by us pursuant to the Shelf Registration Statement. The October 2024